Q2 2026 13F · SEC CIK 1813845
BIOS Capital Management, LP
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $41.7M
- Reported positions
- 6
- Holdings vs S&P 500, 3 yrs
- —
- Assets under management
- $250.9M
BIOS Capital Management, LP is a hedge fund that reported 6 positions worth $41.7M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Actuate Therapeutics Inc (ACTU, 36.9%), Opus Genetics Inc (IRD, 36.3%), Cognition Therapeutics Inc (CGTX, 16.6%).
BIOS Capital Management, LP holdings all 6 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| ACTUActuate Therapeutics Inc | 36.9% | +0.0% | $15.4M |
| IRDOpus Genetics Inc | 36.3% | +0.0% | $15.1M |
| CGTXCognition Therapeutics Inc | 16.6% | +0.0% | $6.9M |
| RNTXRein Therapeutics Inc | 7.4% | +50.4% | $3.1M |
| LTRNLantern Pharma Inc | 2.5% | -71.1% | $1.0M |
| INABIn8bio Inc | 0.3% | -51.8% | $114K |
What BIOS Capital Management, LP bought and sold in Q2 2026, against Q1 2026.
New positions
No new positions among the largest holdings.
Added to
- RNTX Rein Therapeutics Inc+50.4% shares
Reduced
- LTRN Lantern Pharma Inc-71.1% shares
- INAB In8bio Inc-51.8% shares
Sold out
Nothing sold out.
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- -80.3% /yr
- S&P 500 +20.1%
- 3 years
- —
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $41.7M | 6 |
| Q1 2026 | $52.9M | 6 |
| Q4 2025 | $82.6M | 6 |
| Q3 2025 | $88.9M | 6 |
| Q2 2025 | $72.6M | 6 |
| Q1 2025 | $79.2M | 6 |
| Q4 2024 | $94.1M | 6 |
Questions about BIOS Capital Management, LP's portfolio
What stocks does BIOS Capital Management, LP own?
BIOS Capital Management, LP's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 6 positions worth $41.7M. The largest are Actuate Therapeutics Inc (ACTU) at 36.9%, Opus Genetics Inc (IRD) at 36.3%, Cognition Therapeutics Inc (CGTX) at 16.6%, Rein Therapeutics Inc (RNTX) at 7.4% and Lantern Pharma Inc (LTRN) at 2.5%.
What did BIOS Capital Management, LP buy last quarter?
In Q2 2026, BIOS Capital Management, LP added Rein Therapeutics Inc (RNTX) (+50.4% shares), compared with its Q1 2026 filing.
What did BIOS Capital Management, LP sell last quarter?
In Q2 2026, BIOS Capital Management, LP Lantern Pharma Inc (LTRN) (-71.1% shares) and In8bio Inc (INAB) (-51.8% shares), compared with its Q1 2026 filing.
When is BIOS Capital Management, LP's next 13F filing due?
13F filings are due 45 days after each quarter ends. BIOS Capital Management, LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does BIOS Capital Management, LP manage?
BIOS Capital Management, LP reported $250.9M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $41.7M.